Los puntos clave no están disponibles para este artículo en este momento.
Abstract Several statistical methods that are available in the literature to analyze postmarket safety databases, such as the U.S. Federal Drug Administration's (FDA) adverse event reporting system (AERS), for identifying drug-event combinations with disproportionately high frequencies, are subject to high false discovery rates. Here, we propose a likelihood ratio test (LRT) based method and show, via an extensive simulation study, that the proposed method while retaining good power and sensitivity for identifying signals, controls both the Type I error and false discovery rates. The application of the LRT method to the AERS database is illustrated using two datasets; a small dataset consisting of suicidal behavior and mood change-related AE cases for the drug Montelukast, and a large dataset consisting of all possible AE cases reported to FDA during 2004–2008 for the drug Heparin. This article has supplementary material online. Keywords: : AERS databaseDisproportionality signal detectionFalse discovery rateReporting rateSimulation
Huang et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: